Different outcomes among patients with intermediate-risk metastastic renal cell carcinoma treated with first-line tyrosine-kinase inhibitors

• Álvaro Pinto ^[1] ; Jesús Miranda ^[2] ; Ana Pertejo ^[1] ; Mario Álvarez-Maestro ^[3] ; Pilar González-Peramato ^[4] ; Alfredo Aguilera ^[3] ; Eugenia García ^[4] ; Lucía Trilla ^[5] ; Ángelo Gámez ^[5] ; Enrique Espinosa ^[1]
  1. [1] Medical Oncology Department, University Hospital La Paz– IdiPAZ, Madrid, Spain
  2. [2] Medical Oncology Department, QuironSalud University Hospital, Madrid, Spain
  3. [3] Urology Department, University Hospital La Paz–IdiPAZ, Madrid, Spain
  4. [4] Pathology Department, University Hospital La Paz–IdiPAZ, Madrid, Spain
  5. [5] Molecular Oncology and Pathology Lab, University Hospital La Paz–IdiPAZ, Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 2, 2024, págs. 532-537
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction Systemic therapy of patients with metastatic renal cell carcinoma (mRCC) has improved in the past years, with the advent of new immunotherapy-based combinations as a standard treatment option for first-line therapy. Nevertheless, particularly in good-risk patients by IMDC criteria, tyrosine-kinase inhibitors (TKI) may remain as an option for some patients. We reviewed our experience with TKI as first-line therapy for mRCC patients, trying to identify subgroups of patients that may still benefit from this strategy.

    Material and methods All patients with mRCC treated with first-line TKI, and adequate follow-up, in University Hospital La Paz (Madrid, Spain) between 2007 and 2020 were analyzed. Patients treated inside a clinical trial were excluded from this analysis.

    Results A total of 90 patients treated with first-line TKI were included. Regarding IMDC criteria, 33 patients (36.7%) were good-risk, 41 patients (45.5%) intermediate-risk, and 16 patients (17.8%) poor-risk. With a median follow-up of 49 months, the median overall survival (OS) for good, intermediate, and poor-risk patients was 54, 24, and 16 months (p = 0.004). When intermediate-risk was divided into patients with 1 or 2 risk factors, differences in OS were also statistically significant: patients with 1 risk factor had a median OS of 33 months, while patients with 2 risk factors had a median OS of 16 months, the same as poor-risk patients (p = 0.003). In the multivariate analysis, trying to find out which of the IMDC factors had a more remarkable weight in the prognosis of the patients, both ECOG and hemoglobin levels by themselves were significantly associated with OS.

    Conclusion In our group of patients, survival outcomes were different among patients with intermediate-risk with 1 or 2 risk factors by IMDC criteria. These could help select patients that may benefit from first-line treatment with a TKI, particularly in settings with difficult access to novel therapies, such as immunotherapy-based combinations.